Request for Covid-19 Impact Assessment of this Report
The United States Recombinant FVIII market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Recombinant FVIII market, reaching US$ million by the year 2028. As for the Europe Recombinant FVIII landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Recombinant FVIII players cover Bayer, Baxter, Comirnaty, and Novo Nordisk, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant FVIII market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
250 IU/bottle
500 IU/bottle
1000 IU/bottle
2000 IU/bottle
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Teenagers
Adults
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Bayer
Baxter
Comirnaty
Novo Nordisk
Green Cross
Sinocelltech
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant FVIII Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Recombinant FVIII by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Recombinant FVIII by Country/Region, 2017, 2022 & 2028
2.2 Recombinant FVIII Segment by Type
2.2.1 250 IU/bottle
2.2.2 500 IU/bottle
2.2.3 1000 IU/bottle
2.2.4 2000 IU/bottle
2.3 Recombinant FVIII Sales by Type
2.3.1 Global Recombinant FVIII Sales Market Share by Type (2017-2022)
2.3.2 Global Recombinant FVIII Revenue and Market Share by Type (2017-2022)
2.3.3 Global Recombinant FVIII Sale Price by Type (2017-2022)
2.4 Recombinant FVIII Segment by Application
2.4.1 Teenagers
2.4.2 Adults
2.5 Recombinant FVIII Sales by Application
2.5.1 Global Recombinant FVIII Sale Market Share by Application (2017-2022)
2.5.2 Global Recombinant FVIII Revenue and Market Share by Application (2017-2022)
2.5.3 Global Recombinant FVIII Sale Price by Application (2017-2022)
3 Global Recombinant FVIII by Company
3.1 Global Recombinant FVIII Breakdown Data by Company
3.1.1 Global Recombinant FVIII Annual Sales by Company (2020-2022)
3.1.2 Global Recombinant FVIII Sales Market Share by Company (2020-2022)
3.2 Global Recombinant FVIII Annual Revenue by Company (2020-2022)
3.2.1 Global Recombinant FVIII Revenue by Company (2020-2022)
3.2.2 Global Recombinant FVIII Revenue Market Share by Company (2020-2022)
3.3 Global Recombinant FVIII Sale Price by Company
3.4 Key Manufacturers Recombinant FVIII Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant FVIII Product Location Distribution
3.4.2 Players Recombinant FVIII Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Recombinant FVIII by Geographic Region
4.1 World Historic Recombinant FVIII Market Size by Geographic Region (2017-2022)
4.1.1 Global Recombinant FVIII Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Recombinant FVIII Annual Revenue by Geographic Region
4.2 World Historic Recombinant FVIII Market Size by Country/Region (2017-2022)
4.2.1 Global Recombinant FVIII Annual Sales by Country/Region (2017-2022)
4.2.2 Global Recombinant FVIII Annual Revenue by Country/Region
4.3 Americas Recombinant FVIII Sales Growth
4.4 APAC Recombinant FVIII Sales Growth
4.5 Europe Recombinant FVIII Sales Growth
4.6 Middle East & Africa Recombinant FVIII Sales Growth
5 Americas
5.1 Americas Recombinant FVIII Sales by Country
5.1.1 Americas Recombinant FVIII Sales by Country (2017-2022)
5.1.2 Americas Recombinant FVIII Revenue by Country (2017-2022)
5.2 Americas Recombinant FVIII Sales by Type
5.3 Americas Recombinant FVIII Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant FVIII Sales by Region
6.1.1 APAC Recombinant FVIII Sales by Region (2017-2022)
6.1.2 APAC Recombinant FVIII Revenue by Region (2017-2022)
6.2 APAC Recombinant FVIII Sales by Type
6.3 APAC Recombinant FVIII Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant FVIII by Country
7.1.1 Europe Recombinant FVIII Sales by Country (2017-2022)
7.1.2 Europe Recombinant FVIII Revenue by Country (2017-2022)
7.2 Europe Recombinant FVIII Sales by Type
7.3 Europe Recombinant FVIII Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant FVIII by Country
8.1.1 Middle East & Africa Recombinant FVIII Sales by Country (2017-2022)
8.1.2 Middle East & Africa Recombinant FVIII Revenue by Country (2017-2022)
8.2 Middle East & Africa Recombinant FVIII Sales by Type
8.3 Middle East & Africa Recombinant FVIII Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant FVIII
10.3 Manufacturing Process Analysis of Recombinant FVIII
10.4 Industry Chain Structure of Recombinant FVIII
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant FVIII Distributors
11.3 Recombinant FVIII Customer
12 World Forecast Review for Recombinant FVIII by Geographic Region
12.1 Global Recombinant FVIII Market Size Forecast by Region
12.1.1 Global Recombinant FVIII Forecast by Region (2023-2028)
12.1.2 Global Recombinant FVIII Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant FVIII Forecast by Type
12.7 Global Recombinant FVIII Forecast by Application
13 Key Players Analysis
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Recombinant FVIII Product Offered
13.1.3 Bayer Recombinant FVIII Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Baxter
13.2.1 Baxter Company Information
13.2.2 Baxter Recombinant FVIII Product Offered
13.2.3 Baxter Recombinant FVIII Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Baxter Main Business Overview
13.2.5 Baxter Latest Developments
13.3 Comirnaty
13.3.1 Comirnaty Company Information
13.3.2 Comirnaty Recombinant FVIII Product Offered
13.3.3 Comirnaty Recombinant FVIII Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Comirnaty Main Business Overview
13.3.5 Comirnaty Latest Developments
13.4 Novo Nordisk
13.4.1 Novo Nordisk Company Information
13.4.2 Novo Nordisk Recombinant FVIII Product Offered
13.4.3 Novo Nordisk Recombinant FVIII Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Novo Nordisk Main Business Overview
13.4.5 Novo Nordisk Latest Developments
13.5 Green Cross
13.5.1 Green Cross Company Information
13.5.2 Green Cross Recombinant FVIII Product Offered
13.5.3 Green Cross Recombinant FVIII Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Green Cross Main Business Overview
13.5.5 Green Cross Latest Developments
13.6 Sinocelltech
13.6.1 Sinocelltech Company Information
13.6.2 Sinocelltech Recombinant FVIII Product Offered
13.6.3 Sinocelltech Recombinant FVIII Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Sinocelltech Main Business Overview
13.6.5 Sinocelltech Latest Developments
14 Research Findings and Conclusion
Table 1. Recombinant FVIII Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Recombinant FVIII Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of 250 IU/bottle
Table 4. Major Players of 500 IU/bottle
Table 5. Major Players of 1000 IU/bottle
Table 6. Major Players of 2000 IU/bottle
Table 7. Global Recombinant FVIII Sales by Type (2017-2022) & (K Units)
Table 8. Global Recombinant FVIII Sales Market Share by Type (2017-2022)
Table 9. Global Recombinant FVIII Revenue by Type (2017-2022) & ($ million)
Table 10. Global Recombinant FVIII Revenue Market Share by Type (2017-2022)
Table 11. Global Recombinant FVIII Sale Price by Type (2017-2022) & (US$/Unit)
Table 12. Global Recombinant FVIII Sales by Application (2017-2022) & (K Units)
Table 13. Global Recombinant FVIII Sales Market Share by Application (2017-2022)
Table 14. Global Recombinant FVIII Revenue by Application (2017-2022)
Table 15. Global Recombinant FVIII Revenue Market Share by Application (2017-2022)
Table 16. Global Recombinant FVIII Sale Price by Application (2017-2022) & (US$/Unit)
Table 17. Global Recombinant FVIII Sales by Company (2020-2022) & (K Units)
Table 18. Global Recombinant FVIII Sales Market Share by Company (2020-2022)
Table 19. Global Recombinant FVIII Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Recombinant FVIII Revenue Market Share by Company (2020-2022)
Table 21. Global Recombinant FVIII Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers Recombinant FVIII Producing Area Distribution and Sales Area
Table 23. Players Recombinant FVIII Products Offered
Table 24. Recombinant FVIII Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Recombinant FVIII Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Recombinant FVIII Sales Market Share Geographic Region (2017-2022)
Table 29. Global Recombinant FVIII Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Recombinant FVIII Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Recombinant FVIII Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Recombinant FVIII Sales Market Share by Country/Region (2017-2022)
Table 33. Global Recombinant FVIII Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Recombinant FVIII Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Recombinant FVIII Sales by Country (2017-2022) & (K Units)
Table 36. Americas Recombinant FVIII Sales Market Share by Country (2017-2022)
Table 37. Americas Recombinant FVIII Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Recombinant FVIII Revenue Market Share by Country (2017-2022)
Table 39. Americas Recombinant FVIII Sales by Type (2017-2022) & (K Units)
Table 40. Americas Recombinant FVIII Sales Market Share by Type (2017-2022)
Table 41. Americas Recombinant FVIII Sales by Application (2017-2022) & (K Units)
Table 42. Americas Recombinant FVIII Sales Market Share by Application (2017-2022)
Table 43. APAC Recombinant FVIII Sales by Region (2017-2022) & (K Units)
Table 44. APAC Recombinant FVIII Sales Market Share by Region (2017-2022)
Table 45. APAC Recombinant FVIII Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Recombinant FVIII Revenue Market Share by Region (2017-2022)
Table 47. APAC Recombinant FVIII Sales by Type (2017-2022) & (K Units)
Table 48. APAC Recombinant FVIII Sales Market Share by Type (2017-2022)
Table 49. APAC Recombinant FVIII Sales by Application (2017-2022) & (K Units)
Table 50. APAC Recombinant FVIII Sales Market Share by Application (2017-2022)
Table 51. Europe Recombinant FVIII Sales by Country (2017-2022) & (K Units)
Table 52. Europe Recombinant FVIII Sales Market Share by Country (2017-2022)
Table 53. Europe Recombinant FVIII Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Recombinant FVIII Revenue Market Share by Country (2017-2022)
Table 55. Europe Recombinant FVIII Sales by Type (2017-2022) & (K Units)
Table 56. Europe Recombinant FVIII Sales Market Share by Type (2017-2022)
Table 57. Europe Recombinant FVIII Sales by Application (2017-2022) & (K Units)
Table 58. Europe Recombinant FVIII Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa Recombinant FVIII Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Recombinant FVIII Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Recombinant FVIII Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Recombinant FVIII Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Recombinant FVIII Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Recombinant FVIII Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Recombinant FVIII Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa Recombinant FVIII Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Recombinant FVIII
Table 68. Key Market Challenges & Risks of Recombinant FVIII
Table 69. Key Industry Trends of Recombinant FVIII
Table 70. Recombinant FVIII Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Recombinant FVIII Distributors List
Table 73. Recombinant FVIII Customer List
Table 74. Global Recombinant FVIII Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Recombinant FVIII Sales Market Forecast by Region
Table 76. Global Recombinant FVIII Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Recombinant FVIII Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Recombinant FVIII Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Recombinant FVIII Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Recombinant FVIII Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Recombinant FVIII Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Recombinant FVIII Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Recombinant FVIII Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Recombinant FVIII Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Recombinant FVIII Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Recombinant FVIII Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global Recombinant FVIII Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Recombinant FVIII Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Recombinant FVIII Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Recombinant FVIII Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global Recombinant FVIII Sales Market Share Forecast by Application (2023-2028)
Table 92. Global Recombinant FVIII Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global Recombinant FVIII Revenue Market Share Forecast by Application (2023-2028)
Table 94. Bayer Basic Information, Recombinant FVIII Manufacturing Base, Sales Area and Its Competitors
Table 95. Bayer Recombinant FVIII Product Offered
Table 96. Bayer Recombinant FVIII Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Bayer Main Business
Table 98. Bayer Latest Developments
Table 99. Baxter Basic Information, Recombinant FVIII Manufacturing Base, Sales Area and Its Competitors
Table 100. Baxter Recombinant FVIII Product Offered
Table 101. Baxter Recombinant FVIII Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. Baxter Main Business
Table 103. Baxter Latest Developments
Table 104. Comirnaty Basic Information, Recombinant FVIII Manufacturing Base, Sales Area and Its Competitors
Table 105. Comirnaty Recombinant FVIII Product Offered
Table 106. Comirnaty Recombinant FVIII Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. Comirnaty Main Business
Table 108. Comirnaty Latest Developments
Table 109. Novo Nordisk Basic Information, Recombinant FVIII Manufacturing Base, Sales Area and Its Competitors
Table 110. Novo Nordisk Recombinant FVIII Product Offered
Table 111. Novo Nordisk Recombinant FVIII Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. Novo Nordisk Main Business
Table 113. Novo Nordisk Latest Developments
Table 114. Green Cross Basic Information, Recombinant FVIII Manufacturing Base, Sales Area and Its Competitors
Table 115. Green Cross Recombinant FVIII Product Offered
Table 116. Green Cross Recombinant FVIII Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. Green Cross Main Business
Table 118. Green Cross Latest Developments
Table 119. Sinocelltech Basic Information, Recombinant FVIII Manufacturing Base, Sales Area and Its Competitors
Table 120. Sinocelltech Recombinant FVIII Product Offered
Table 121. Sinocelltech Recombinant FVIII Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. Sinocelltech Main Business
Table 123. Sinocelltech Latest Developments
List of Figures
Figure 1. Picture of Recombinant FVIII
Figure 2. Recombinant FVIII Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant FVIII Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Recombinant FVIII Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Recombinant FVIII Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of 250 IU/bottle
Figure 10. Product Picture of 500 IU/bottle
Figure 11. Product Picture of 1000 IU/bottle
Figure 12. Product Picture of 2000 IU/bottle
Figure 13. Global Recombinant FVIII Sales Market Share by Type in 2021
Figure 14. Global Recombinant FVIII Revenue Market Share by Type (2017-2022)
Figure 15. Recombinant FVIII Consumed in Teenagers
Figure 16. Global Recombinant FVIII Market: Teenagers (2017-2022) & (K Units)
Figure 17. Recombinant FVIII Consumed in Adults
Figure 18. Global Recombinant FVIII Market: Adults (2017-2022) & (K Units)
Figure 19. Global Recombinant FVIII Sales Market Share by Application (2017-2022)
Figure 20. Global Recombinant FVIII Revenue Market Share by Application in 2021
Figure 21. Recombinant FVIII Revenue Market by Company in 2021 ($ Million)
Figure 22. Global Recombinant FVIII Revenue Market Share by Company in 2021
Figure 23. Global Recombinant FVIII Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global Recombinant FVIII Revenue Market Share by Geographic Region in 2021
Figure 25. Global Recombinant FVIII Sales Market Share by Region (2017-2022)
Figure 26. Global Recombinant FVIII Revenue Market Share by Country/Region in 2021
Figure 27. Americas Recombinant FVIII Sales 2017-2022 (K Units)
Figure 28. Americas Recombinant FVIII Revenue 2017-2022 ($ Millions)
Figure 29. APAC Recombinant FVIII Sales 2017-2022 (K Units)
Figure 30. APAC Recombinant FVIII Revenue 2017-2022 ($ Millions)
Figure 31. Europe Recombinant FVIII Sales 2017-2022 (K Units)
Figure 32. Europe Recombinant FVIII Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa Recombinant FVIII Sales 2017-2022 (K Units)
Figure 34. Middle East & Africa Recombinant FVIII Revenue 2017-2022 ($ Millions)
Figure 35. Americas Recombinant FVIII Sales Market Share by Country in 2021
Figure 36. Americas Recombinant FVIII Revenue Market Share by Country in 2021
Figure 37. United States Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC Recombinant FVIII Sales Market Share by Region in 2021
Figure 42. APAC Recombinant FVIII Revenue Market Share by Regions in 2021
Figure 43. China Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 47. India Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe Recombinant FVIII Sales Market Share by Country in 2021
Figure 50. Europe Recombinant FVIII Revenue Market Share by Country in 2021
Figure 51. Germany Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 52. France Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa Recombinant FVIII Sales Market Share by Country in 2021
Figure 57. Middle East & Africa Recombinant FVIII Revenue Market Share by Country in 2021
Figure 58. Egypt Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country Recombinant FVIII Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of Recombinant FVIII in 2021
Figure 64. Manufacturing Process Analysis of Recombinant FVIII
Figure 65. Industry Chain Structure of Recombinant FVIII
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...